Moderna could know whether its CCP virus vaccine candidate is effective by the end of October, chief executive officer Stephane Bancel said Thursday.
Bancel said that the timing of the results of a large, pivotal study on the company’s CCP (Chinese Communist Party) virus vaccine was dependent on the rates of infection in the areas where trials are being carried out in the United States. He said this is because the study is comparing the number symptomatic virus cases between unvaccinated individuals and those who have received a shot.